Table 3.

Univariate analyses for recurrence-free-survival and overall survival in patients with a diagnosis of localised mixed neuroendocrine non-neuroendocrine neoplasm

	RFS				OS
	n	Median (mo)	95%CI	P value	n	Median (mo)	95%CI	P value
Primary tumour site
Lower GI	25	15.70	10.1-NR	0.28	25	29.6	19.1-NR	< 0.001
PB	4	8.11	2.9-NR		4	8.6	7.6-NR
Upper GI	5	14.89	8.0-NR		5	20.4	9.4-NR
Unknown	0				0
Age at diagnosis
< 70 yr	22	15.5	11.5-NR	0.023	22	32.6	20.7-NR	0.017
≥ 70 yr	12	9.2	6.5-NR		12	16.1	8.6-NR
ECOG PS
0-1	27	12.7	9.2-NR	0.29	27	29.6	18.3-NR	0.34
≥ 2	5	18.5	5.7-NR		5	28.6	14.3-NR
Gender
Female	14	7.0	4.2-NR	0.081	14	11.9	8.6-NR	0.037
Male	20	15.5	11.5-NR		20	32.6	19.1-NR
Predominant component
ADC	9	11.5	6.4-NR	0.99	9	20.7	15.9-NR	0.66
EQUAL	2	8.1	-		2	-	-
NE	14	12.7	7.0-NR		14	20.4	18.3-NR
Grading NE component
G1	2	-	-	0.16	2	-	-	0.24
G2	2	33.7	24.4-NR		2	36.7	29.6-NR
G3	29	11.5	8.0-18.5		29	20.7	15.9-NR
Ki-67 of NE component
< 55%	9	17.1	2.9-NR	0.67	9	28.6	8.6-NR	0.83
≥ 55%	17	9.2	7.0-NR		17	19.1	14.3-NR
pN+
No	4	-	-	0.015	4	-	-	0.069
Yes	16	10.1	6.5		16	28.6	14.3-NR
Periop-treatment
No	13	14.0	7.0-NR	0.375	13	28.6	16.1-NR	0.24
Yes	19	14.9	8.0-NR		19	20.4	14.3-NR

RFS: Recurrent free survival; OS: Overall survival; 95%CI: 95% confidence interval; NR: Not reached; Lower GI: Lower gastrointestinal tract; Upper GI: Upper gastrointestinal tract; PB: Pancreatico-biliary tract; PS: Performance status; ECOG: Eastern Cooperative Oncology Group; ADC: Adenocarcinoma; EQUAL: Equal proportions of the two histologies; NE: Neuroendocrine component; pN+: Presence of metastatic loco-regional lymph nodes on post-operative pathological examination; Periop: Perioperative.